New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
08:41 EDTFINL, FL, LULU, LLY, AUO, FOLD, SONC, ARAYOn The Fly: Pre-market Movers
HIGHER AFTER GUIDANCE: Eli Lilly (LLY), up 1.7%... ALSO HIGHER: Amicus Theraputics (FOLD), up 8.5% after announcing results from Phase 2 study... AU Optronics (AUO), up 4.7% after DigiTimes said company asked to join Amazon supply chain... LOWER AFTER EARNINGS/GUIDANCE: Finish Line (FINL), down 7%... Sonic (SONC), down 5%... Accuray (ARAY), down 25.5%... ALSO LOWER: Foot Locker (FL), down 2% after disappointing results, guidance of peer Finish Line... lululemon (LULU), down 3.9% after downgrade to Neutral at Credit Suisse.
News For FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
15:27 EDTLULUlululemon management to meet with William Blair
Subscribe for More Information
13:49 EDTLLYEarnings Preview: Lilly looks to rebound from recent patent expirations
Eli Lilly and Company (LLY) is scheduled to report third quarter earnings before the market open on Thursday, October 23 with a conference call scheduled for 9:00 am ET. Lilly is a global pharmaceutical manufacturer that also has an animal health business segment. EXPECTATIONS: Analysts are looking for earnings per share of 67c on revenue of $4.83B, according to First Call. The consensus range for EPS is 60c-77c on revenue of $4.75B-$4.92B. LAST QUARTER: Eli Lilly reported second quarter EPS of 68c, which beat consensus estimates, on revenue of $4.94B against estimates of $4.9B. Lilly reaffirmed its FY14 EPS and revenue view at the time. The company said it sees FY14 EPS of $2.72-$2.80 on revenue of $19.4B-$20.0B, against consensus estimates of $2.78 and $19.93B respectively. Lilly's CEO John Lechleiter commented on the quarter, "Lilly's second-quarter results reflect a substantial decline in revenue and earnings resulting from recent patent expirations. At the same time, new product approvals and impending launches give us great confidence that Lilly is poised for growth in the years ahead. We have stayed the course with our innovation-based strategy, replenishing and advancing our pipeline. We remain firm in our commitment to sustain and accelerate a flow of important new medicines that make life better for people around the world." STREET RESEARCH: In late August, Deutsche Bank initiated coverage of the name with a Buy rating and a $71 price target. PRICE ACTION: Lilly shares are relatively flat since the company's last earnings report on July 24, and they are trading up fractionally to $64.95 in midday trading ahead of tomorrow's earnings release.
07:35 EDTLLYCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
04:57 EDTLULUlululemon partners with Dalai Lama Center
Subscribe for More Information
October 21, 2014
16:16 EDTSONCSonic sees FY15 EPS growth 18%-20%
Subscribe for More Information
16:14 EDTSONCSonic reports Q4 EPS 34c, consensus 34c
Subscribe for More Information
15:30 EDTSONCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Yahoo! (YHOO), consensus 30c; ACE (ACE), consensus $2.34; Discover Financial (DFS), consensus $1.34; Pinnacle Financial (PNFP), consensus 51c; Broadcom (BRCM), consensus 84c; Intuitive Surgical (ISRG), consensus $3.80; FMC Technologies (FTI), consensus 74c; Robert Half International (RHI), consensus 58c; E-Trade (ETFC), consensus 22c; Nabors Industries (NBR), consensus 36c; Waste Connections (WCN), consensus 54c; Cubist Pharmaceuticals (CBST), consensus 4c; Sonic (SONC), consensus 34c; American Campus Communities (ACC), consensus 43c; Cree (CREE), consensus 36c; Fulton Financial (FULT), consensus 20c; Costamare (CMRE), consensus 41c; Hawaiian Holdings (HA), consensus 78c; Ethan Allen (ETH), consensus 36c; Sabra Health (SBRA), consensus 55c; Rush Enterprises (RUSHA), consensus 51c.
08:32 EDTLLYFDA accepted NDA for empagliflozin plus
Subscribe for More Information
07:32 EDTFINLFinish Line names Samuel Sato as president
Subscribe for More Information
07:15 EDTLLYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
08:11 EDTFINLFinish Line management to meet with Deutsche Bank
Meeting to be held in New York on October 20 hosted by Deutsche Bank.
07:12 EDTARAYCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:10 EDTFOLDAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 19, 2014
19:46 EDTFOLDAmicus announces additional positive data from from Fabry monotherapy study
Subscribe for More Information
October 17, 2014
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
06:14 EDTFLFoot Locker pullback a buying opportunity, says Citigroup
Subscribe for More Information
October 16, 2014
14:36 EDTLLYLilly to close Guayama facility, will take 16c charge in Q4
Eli Lilly announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. All of the approximately 100 full-time non-contracted employees currently working in Guayama will be offered employment at Lilly's Carolina, Puerto Rico, location. As a result of this action, the company expects to record a charge of approximately $170M or approximately 16c per share, after tax, in Q414. While Lilly will initiate efforts to sell the Guayama site, the company will continue to invest in two manufacturing plants at Carolina. In November 2013, Lilly announced a $200M investment to increase capacity in its Carolina-based insulin active ingredient manufacturing plant. In July, Lilly announced an additional $40M in investments to increase capabilities at its Carolina-based drug product site as part of a rebalancing of Lilly's oral solid dosage network.
10:01 EDTLULUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Akamai (AKAM) downgraded to Market Perform from Outperform at Wells Fargo... CGG SA (CGG) downgraded to Reduce from Neutral at Nomura... Central Valley Community (CVCY) downgraded to Hold from Buy at Sandler O'Neill... DSM (RDSMY) downgraded to Neutral from Buy at Nomura... Disney (DIS) downgraded at Guggenheim... Francesca's (FRAN) downgraded to Underperform from Outperform at Macquarie... Netflix (NFLX) downgraded to Fair Value from Buy at CRT Capital... Nordstrom (JWN) downgraded to Neutral from Outperform at Macquarie... Norfolk Southern (NSC) downgraded at Credit Suisse... Rio Tinto (RIO) downgraded to Market Perform at Cowen... Seadrill (SDRL) downgraded to Reduce from Neutral at Nomura... Ternium (TX) downgraded to Neutral from Overweight at JPMorgan... Urban Outfitters (URBN) downgraded to Neutral from Outperform at Macquarie... Viacom (VIAB) downgraded at BofA/Merrill... eBay (EBAY) downgraded to Underperform from Buy at CLSA... lululemon (LULU) downgraded to Underperform from Neutral at Macquarie.
09:34 EDTAUOAU Optronics downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
05:39 EDTLULUlululemon downgraded to Underperform from Neutral at Macquarie
Macquarie downgraded lululemon to Underperform after assuming coverage of the stock saying the company's expansion into Asia and Europe will drive a meaningful increase in spending. The firm lowered its price target for shares to $34 from $40.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use